Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Pharmacology

Background:

• Cardiovascular disease remains a leading cause of mortality globally.
• Identifying effective preventative strategies for intermediate-risk individuals is crucial.
• Previous research has explored the benefits of statins and antihypertensives separately.

Purpose of the Study:

• To evaluate the combined and individual effects of statin and antihypertensive therapy on cardiovascular events.
• To assess the efficacy of rosuvastatin and candesartan plus hydrochlorothiazide in intermediate-risk populations.

Main Methods:

• A large-scale, 2x2 factorial randomized controlled trial involving 12,705 participants across 21 countries.
• Participants were assigned to rosuvastatin or placebo, candesartan/hydrochlorothiazide or placebo, and a combination therapy or dual placebo.
• Median follow-up duration was 5.6 years.

Main Results:

• Combination therapy of antihypertensives and statins significantly reduced cardiovascular events compared to dual placebo.
• Statin therapy alone demonstrated a significant benefit in improving cardiovascular outcomes.
• Antihypertensive therapy, when used alone, did not provide a statistically significant added benefit over placebo.

Conclusions:

• Combined statin and antihypertensive therapy is highly effective in preventing cardiovascular events in intermediate-risk individuals.
• Statin therapy is beneficial for cardiovascular risk reduction in this population.
• The addition of antihypertensive therapy to statins provides significant benefits beyond statin therapy alone.